1. Home
  2. AKBA vs ANGI Comparison

AKBA vs ANGI Comparison

Compare AKBA & ANGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKBA
  • ANGI
  • Stock Information
  • Founded
  • AKBA 2007
  • ANGI 1995
  • Country
  • AKBA United States
  • ANGI United States
  • Employees
  • AKBA N/A
  • ANGI N/A
  • Industry
  • AKBA Biotechnology: Pharmaceutical Preparations
  • ANGI Advertising
  • Sector
  • AKBA Health Care
  • ANGI Consumer Discretionary
  • Exchange
  • AKBA Nasdaq
  • ANGI Nasdaq
  • Market Cap
  • AKBA 669.7M
  • ANGI 566.2M
  • IPO Year
  • AKBA 2014
  • ANGI 2017
  • Fundamental
  • Price
  • AKBA $3.69
  • ANGI $16.61
  • Analyst Decision
  • AKBA Strong Buy
  • ANGI Buy
  • Analyst Count
  • AKBA 5
  • ANGI 8
  • Target Price
  • AKBA $6.90
  • ANGI $21.36
  • AVG Volume (30 Days)
  • AKBA 6.0M
  • ANGI 1.2M
  • Earning Date
  • AKBA 05-08-2025
  • ANGI 08-05-2025
  • Dividend Yield
  • AKBA N/A
  • ANGI N/A
  • EPS Growth
  • AKBA N/A
  • ANGI N/A
  • EPS
  • AKBA N/A
  • ANGI 1.03
  • Revenue
  • AKBA $184,909,000.00
  • ANGI $1,125,635,000.00
  • Revenue This Year
  • AKBA $23.32
  • ANGI N/A
  • Revenue Next Year
  • AKBA $49.90
  • ANGI $4.06
  • P/E Ratio
  • AKBA N/A
  • ANGI $16.33
  • Revenue Growth
  • AKBA N/A
  • ANGI N/A
  • 52 Week Low
  • AKBA $0.80
  • ANGI $10.88
  • 52 Week High
  • AKBA $3.73
  • ANGI $29.15
  • Technical
  • Relative Strength Index (RSI)
  • AKBA 83.69
  • ANGI 60.49
  • Support Level
  • AKBA $2.76
  • ANGI $15.46
  • Resistance Level
  • AKBA $3.73
  • ANGI $17.16
  • Average True Range (ATR)
  • AKBA 0.18
  • ANGI 0.59
  • MACD
  • AKBA 0.07
  • ANGI 0.01
  • Stochastic Oscillator
  • AKBA 96.67
  • ANGI 67.35

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About ANGI Angi Inc.

Angi Inc connects quality home service professionals with consumers across different categories, from repairing and remodeling to cleaning and landscaping. It operates through brands like Angi, HomeAdvisor, and Handy. The company has three operating segments, namely, Ads and Leads, Services, and International (Europe and Canada). A majority of its revenue is generated from the Ads and Leads segment, which provides professionals the capability to engage with potential customers, including quoting and invoicing services, and provides consumers with tools and resources to help them find professionals nationwide for home repair, maintenance, and improvement projects. Geographically, the company derives its key revenue from the United States and also has a presence in other countries.

Share on Social Networks: